Live Breaking News & Updates on Lara meisner

Stay updated with breaking news from Lara meisner. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Bought by Commodore Capital LP

Commodore Capital LP boosted its position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN – Free Report) by 8.4% in the 1st quarter, HoldingsChannel reports. The fund owned 2,189,659 shares of the company’s stock after acquiring an additional 169,493 shares during the period. Viridian Therapeutics accounts for about 8.5% of Commodore Capital LP’s portfolio, making the […]

Canada , Hood-river , Nunavut , Lara-meisner , Renaissance-technologies , Kopp-family-office , Hood-river-capital-management , Ghost-tree-capital , Deutsche-bank , Securities-exchange-commission , Nasdaq , Viridian-therapeutics-company-profile

Hood River Capital Management LLC Takes $14.41 Million Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Hood River Capital Management LLC bought a new stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN – Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 566,498 shares of the company’s stock, valued at approximately $14,412,000. Hood River Capital Management LLC owned […]

Canada , Hood-river , Nunavut , Lara-meisner , Group-plc , Wells-fargo-company , Viridian-therapeutics-inc , Viridian-therapeutics-company-profile , Securities-exchange-commission , Life-insurance-co , Tower-research-capital , Hood-river-capital-management

Hood River Capital Management LLC Purchases Shares of 566,498 Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Hood River Capital Management LLC purchased a new stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN – Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 566,498 shares of the company’s stock, valued at approximately $14,412,000. Several other hedge […]

Canada , Hood-river , Nunavut , Lara-meisner , Charles-schwab-investment-management-inc , Hood-river-capital-management , Exchange-commission , Viridian-therapeutics-inc , Needham-company , Royal-bank , Securities-exchange-commission , Nasdaq

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives $43.14 Consensus PT from Analysts

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives $43.14 Consensus PT from Analysts
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Canada , Lara-meisner , Securities-exchange-commission , Viridian-therapeutics-inc , Principal-financial-group-inc , Mirae-asset-global-investments-co , Life-insurance-co , Nasdaq , Royal-bank , Wells-fargo-company , Viridian-therapeutics , Get-free-report

Viridian Therapeutics (VRDN) – Analysts' Weekly Ratings Updates

Viridian Therapeutics (VRDN) – Analysts' Weekly Ratings Updates
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Canada , Lara-meisner , Securities-exchange-commission , Needham-company , Oppenheimer-holdings-inc , Royal-bank , News-ratings-for-viridian-therapeutics-inc-daily , Viridian-therapeutics-inc , Wells-fargo-company , Perceptive-advisors , Viridian-therapeutics , Wells-fargo

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Expected to Earn Q3 2023 Earnings of ($1.31) Per Share

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Expected to Earn Q3 2023 Earnings of ($1.31) Per Share
kopsource.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kopsource.com Daily Mail and Mail on Sunday newspapers.

Canada , Lara-meisner , Viridian-therapeutics-inc , Viridian-therapeutics-company-profile , Wells-fargo-company , Tower-research-capital , Life-insurance-co , Nasdaq , Royal-bank , Silverarc-capital-management , Viridian-therapeutics , Free-report

JMP Securities Trims Viridian Therapeutics (NASDAQ:VRDN) Target Price to $42.00

JMP Securities Trims Viridian Therapeutics (NASDAQ:VRDN) Target Price to $42.00
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Canada , Lara-meisner , Viridian-therapeutics-company-profile , Wells-fargo-company , Royal-bank , Securities-exchange-commission , Viridian-therapeutics-inc , Driehaus-capital-management , Principal-financial-group-inc , Nasdaq , Vivo-capital , Viridian-therapeutics

Viridian Therapeutics (NASDAQ:VRDN) Price Target Cut to $39.00 by Analysts at Wells Fargo & Company

Viridian Therapeutics (NASDAQ:VRDN – Free Report) had its target price reduced by Wells Fargo & Company from $46.00 to $39.00 in a report published on Wednesday, Marketbeat.com reports. They currently have an overweight rating on the stock. VRDN has been the subject of several other reports. Royal Bank of Canada began coverage on shares of […]

Canada , Lara-meisner , Wells-fargo-company , Tower-research-capital , Viridian-therapeutics-inc , Life-insurance-co , Silverarc-capital-management , Royal-bank , Viridian-therapeutics , Free-report , Wells-fargo , Get-free-report

Viridian Therapeutics (NASDAQ:VRDN) Given New $39.00 Price Target at Wells Fargo & Company

Viridian Therapeutics (NASDAQ:VRDN – Free Report) had its price objective decreased by Wells Fargo & Company from $46.00 to $39.00 in a research report sent to investors on Wednesday, MarketBeat.com reports. Wells Fargo & Company currently has an overweight rating on the stock. Other equities analysts have also recently issued reports about the company. JMP […]

Canada , Lara-meisner , Life-insurance-co , Viridian-therapeutics-inc , Silverarc-capital-management , Royal-bank , Group-plc , Nasdaq , Wells-fargo-company , Tower-research-capital , Viridian-therapeutics-company-profile , Viridian-therapeutics